Overview

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Status:
Completed

Trial end date:
2005-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare overall survival in patients with previously-treated metastatic, epidermal growth factor receptor (EGFR)-positive colorectal cancer treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) and cetuximab with FOLFOX4 alone.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company
ImClone LLC

Collaborator:

Bristol-Myers Squibb

Treatments:

Cetuximab
Fluorouracil
Leucovorin
Oxaliplatin